GlassScriptPhysician profile
Ara Shafrazian
NPI 1053706234
$1,750.56
in general payments reported to CMS, 2019-2025
17 companies · $49.06 in 2025
The $49.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $537 · 2021: $52.13 · 2022: $145 · 2023: $176 · 2024: $490 · 2025: $49.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.17 | 2023-2025 | Linzess, Viberzi, Creon |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.94 | 2020-2022 | |
| Allergan, INC. | $180.50 | 2019-2022 | |
| Amgen INC. | $170.65 | 2020-2025 | Repatha, Otezla, Repatha |
| Edwards Lifesciences Corporation | $149.06 | 2020 | |
| Boston Scientific Corporation | $108.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $80.40 | 2020-2024 | Xarelto |
| Lilly USA, LLC | $64.37 | 2019-2024 | Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $60.41 | 2020-2024 | |
| Glaxosmithkline, LLC. | $57.07 | 2020-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.12 | 2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $41.69 | 2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $33.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.99 | 2023 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.00 | 2019 | |
| Merck Sharp & Dohme LLC | $17.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Shafrazian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.